# US 2021/0172018 A1 · Genetic variant panels and methods of generation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172018 A1
- Document ID: US20210172018A1
- Status: Published application
- Kind: A1
- Application number: 17/174,902
- Filed: 2021-02-12
- Published: 2021-06-10
- Earliest claimed: 2019-09-23
- Assignees: Synthego Corporation
- Applicants: Synthego Corporation
- Inventors: Richard Stoner; Jason Steiner; Travis Maures; Reed Kelso; Aliesha Griffin
- Web page: https://patentgrep.com/patent/US20210172018A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1075: {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/907: {in mammalian cells}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are methods for generating and using variant panels of clonally expanded cells containing a plurality of introduced genetic variants. These clonally expanded cells can be partitioned such that each individual partition contains a single genetic variant, allowing for the assessment of the outcome of each variant without the confounding effect of background genetic variation. Further, panels of such variants can be used to evaluate nucleic acid repair strategies. Genetic variation can be introduced through the use of genome editing tools, such as CRISPR/Cas.

## Claims

### Claim 1

A method for determining one or more outcomes of one or more nucleic acid edits, the method comprising:
(a) obtaining one or more partitions of clonal cells, wherein each clonal cell in a partition is clonally expanded from a single cell obtained from contacting one or more original cells with the one or more nucleic acid editing units, and wherein the clonal cells comprise at least one nucleic acid edit in one or more genomic regions of interest; and
(b) determining one or more outcomes of the one or more nucleic acid edits by comparing one or more features of clonal cells in the partition of clonal cells to one or more features of cells in the one or more original cells.

### Claim 2 (depends on 1)

The method of claim 1, further comprising comparing one or more features of clonal cells in one partition to one or more features of clonal cells in another partition of a plurality of partitions of clonal cells comprising identical one or more nucleic acid edits in one or more genomic regions of interest.

### Claim 3 (depends on 1)

The method of claim 1, wherein the clonal cell is not obtained via a selection.

### Claim 4 (depends on 3)

The method of claim 3, wherein the selection is based on one or more of: survival, fitness, expression of a protein and expression of an antibiotic.

### Claim 5 (depends on 4)

The method of claim 4, wherein the protein is a fluorescently labeled protein.

### Claim at position 6

-47. (canceled)

### Claim 48

A method for modifying one or more outcomes of one or more first nucleic acid edits in a first genomic region of interest, the method comprising:
(a) obtaining one or more partitions of clonal cells, wherein each partition of clonal cells comprises a first nucleic acid edit from the one or more first nucleic acid edits in a first genomic region of interest, and wherein each clonal cell in a partition is clonally expanded from a single cell obtained from contacting one or more original cells with one or more first nucleic acid editing units; and
(b) contacting each partition of clonal cells with one or more second nucleic acid editing units, wherein each second nucleic acid editing unit is designed to introduce a second nucleic acid edit in a second genomic region of interest thereby producing one or more partitions of twice edited cells, and wherein an outcome of the second nucleic acid edit modifies the outcome of the first nucleic acid edit.

### Claim 49 (depends on 48)

The method of claim 48, wherein each twice edited cell in a partition is clonally expanded from a single cell obtained from contacting each partition of clonal cells with one or more second nucleic acid editing units.

### Claim 50 (depends on 48)

The method of claim 48, wherein the clonal cell is not obtained via a selection.

### Claim at position 10

-110. (canceled)

### Claim 111

A method for generating a variant panel, the method comprising:
(a) contacting one or more original cells with one or more nucleic acid editing units, wherein each editing unit is designed to introduce at least one nucleic acid edit from one or more nucleic acid edits into one or more genomic regions of interest;
(b) isolating at least one single cell from the one or more original cells contacted with the one or more nucleic acid editing units; and
(c) expanding each single cell in one or more partitions thereby generating one or more partitions of clonal cells.

### Claim 112 (depends on 111)

The method of claim 111, wherein the clonal cell is not obtained via a selection.

### Claim 113 (depends on 112)

The method of claim 112, wherein the selection is based on one or more of: survival, fitness, expression of a protein and expression of an antibiotic.

### Claim 114 (depends on 113)

The method of claim 113, wherein the protein is a fluorescently labeled protein.

### Claim 115 (depends on 111)

The method of claim 111, wherein the method comprises contacting one or more original cells in one or more partitions with one or more nucleic acid editing units.

### Claim at position 16

-205. (canceled)

### Claim 206

A variant panel comprising: one or more partitions of clonal cells, wherein each clonal cell in a partition is clonally expanded from a single cell obtained from contacting one or more original cells with the one or more nucleic acid editing units, and wherein the clonal cells comprise at least one nucleic acid edit in one or more genomic regions of interest.

### Claim 207 (depends on 206)

The variant panel of claim 206, wherein the clonal cell is not obtained via a selection.

### Claim 208 (depends on 207)

The variant panel of claim 207, wherein the selection is based on one or more of: survival, fitness, expression of a protein and expression of an antibiotic.

### Claim 209 (depends on 208)

The variant panel of claim 208, wherein the protein is a fluorescently labeled protein.

### Claim 210 (depends on 206)

The variant panel of claim 206, wherein the cells in the one or more partitions of clonal cells are isogenic outside of the one or more genomic regions of interest.

### Claim at position 22

-258. (canceled)
